

# Global Drugs For Benign Prostatic Hypertrophy Market Drivers, Trends And Restraints For 2022-2031

*The Business Research Company's Drugs For Benign Prostatic Hypertrophy Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026*

LONDON, GREATER LONDON, UK, August 8, 2022 /EINPresswire.com/ -- As per The Business Research Company's "Drugs For Benign Prostatic Hypertrophy Global Market Report 2022", the drugs for benign prostatic hypertrophy market size is expected to grow from \$5.93 billion in 2021 to \$6.46 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The drugs for benign prostatic hypertrophy market growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global market share is expected to reach \$8.57 billion in 2026 at a CAGR of 7.3%. According to the [drugs for benign prostatic hypertrophy industry](#) analysis, the rising male geriatric population globally is driving the market as the condition is commonly seen in men aged over 50 years.

Request a Sample now to gain a better understanding of drugs for benign prostatic hypertrophy market:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2594&type=smp>

## Key Trends In The Drugs For Benign Prostatic Hypertrophy Market

Combination drugs are increasingly being used in the treatment of Benign Prostatic Hypertrophy as they are more effective and help prevent disease progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance, have fewer side effects and low treatment failure rate. For instance, Duodart, a combination of dutasteride and tamsulosin hydrochloride is increasingly being prescribed for the treatment of Benign Prostatic Hypertrophy.

## [Overview Of The Drugs For Benign Prostatic Hypertrophy Market](#)

The drugs for benign prostatic hypertrophy market consists of sales of benign prostatic hypertrophy drugs to treat enlarged prostate glands. Benign Prostatic Hypertrophy is commonly seen in men older than age 50.

Learn more on the global drugs for benign prostatic hypertrophy market report at:

<https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report>

Drugs For Benign Prostatic Hypertrophy Global Market Report 2022 from TBRC covers the following information:

Market Size Data

- Forecast period: Historical and Future
- By region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- By countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Market Segmentation

- By Type: Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others
- By End-User: Hospital Pharmacies, Retail Pharmacies, Others
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By Geography: The global drugs for benign prostatic hypertrophy market report is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America holds the largest share in the market.

Major market players such as Allergan PLC, Astellas Pharma Inc., Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi, Nymox Pharmaceutical Corporation and AEternaZentaris Inc.

Trends, opportunities, strategies and so much more.

Drugs For Benign Prostatic Hypertrophy Global Market Report 2022 is one of The Business Research Company's comprehensive reports that provides an overview of drugs for benign prostatic hypertrophy market. The market report analyzes drugs for benign prostatic hypertrophy market size, drugs for benign prostatic hypertrophy market growth drivers, drugs for benign prostatic hypertrophy global market segments, drugs for benign prostatic hypertrophy global market major players, drugs for benign prostatic hypertrophy global market growth across geographies, and drugs for benign prostatic hypertrophy market competitors' revenues and market positioning. The drugs for benign prostatic hypertrophy market report enables you to gain insights on opportunities and strategies, as well as identify countries and segments with the highest growth potential.

Not what you were looking for? Go through similar reports by The Business Research Company:

Prostate Cancer Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report>

Biopsy Devices Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biopsy-devices-market-report>

## Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-bph-treatment-devices-and-equipment-global-market-report>

### About The Business Research Company

The Business Research Company has published over 3000 industry reports, covering over 3000 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

The Business Research Company

Email: [info@tbrc.info](mailto:info@tbrc.info)

Follow us on LinkedIn: <https://bit.ly/3b7850r>

Follow us on Twitter: <https://bit.ly/3b1rmjS>

Check out our Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/584985487>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.